XERSXeris Biopharma Holdings, Inc.
Is it growing?
Growing: revenue growing +36% year on year and operating margin widening (+15.9 points).
Trailing-twelve-month revenue vs a year earlier, from the company's own filings.
Trailing-twelve-month operating margin, 10.9% now against -5.0% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is XERS growing?
Xeris Biopharma Holdings, Inc. has grown revenue 36% a year over three years and 59% a year over five.
Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · compounding fast · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +59%
Revenue growth, 5-year rate · +36% over three · growth has slowed since the five-year average
- Years of annual history on file
- 6
Years of annual history on file · FY2020 to FY2025, as filed
Details›
- Revenue FY2021
- $50M
- Revenue FY2022
- $110M
- Revenue FY2023
- $164M
- Revenue FY2024
- $203M
- Revenue FY2025
- $292M
Annual income statements as filed with the SEC.
Drug Manufacturers, Specialty & Generic
Ranks #25 of 41 by RyuScore